-+ 0.00%
-+ 0.00%
-+ 0.00%

Coherus Q1 FY26 operating loss narrows to $36.15 million; revenue rises to $12.31 million

PUBT·05/11/2026 20:06:46
Listen to the news
Coherus Q1 FY26 operating loss narrows to $36.15 million; revenue rises to $12.31 million
  • Coherus Oncology posted Q1 2026 net revenue of USD 12.3 million, while net loss from continuing operations narrowed to USD 36.9 million, or USD 0.27 per share.
  • Cost of goods sold rose to USD 3.8 million, while R&D expense fell to USD 21.5 million.
  • SG&A expense declined to USD 23.1 million, driven by lower headcount and decreased operating costs following completion of the exit from the biosimilar business in 2025.
  • LOQTORZI net product revenue climbed 61% year over year to USD 11.8 million, while slipping 5% from Q4 2025.
  • Cash, cash equivalents and marketable securities totaled USD 167 million; enrollment completed in randomized Phase 2 casdozokitug/toripalimab/bevacizumab trial in first-line unresectable HCC with first data readout expected mid-2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coherus Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605111605PRIMZONEFULLFEED9717764) on May 11, 2026, and is solely responsible for the information contained therein.